Zydus Lifesciences Ltd announced that Mamitra, a Trastuzumab biosimilar for treating breast and advanced gastric cancer, received marketing approval from Mexico’s COFEPRIS. The approval allows its marketing in 150 mg and 440 mg strengths. Launched in India in 2016, Mamitra has since treated an estimated 1 lakh patients.